These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 24019127)

  • 1. Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta-analysis.
    Singh S; Edakkanambeth Varayil J; Loftus EV; Talwalkar JA
    Liver Transpl; 2013 Dec; 19(12):1361-9. PubMed ID: 24019127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colorectal cancer in patients with inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis.
    Vera A; Gunson BK; Ussatoff V; Nightingale P; Candinas D; Radley S; Mayer A; Buckels JA; McMaster P; Neuberger J; Mirza DF
    Transplantation; 2003 Jun; 75(12):1983-8. PubMed ID: 12829898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis.
    Mouchli MA; Singh S; Boardman L; Bruining DH; Lightner AL; Rosen CB; Heimbach JK; Hasan B; Poterucha JJ; Watt KD; Kane SV; Raffals LE; Loftus EV
    Inflamm Bowel Dis; 2018 Apr; 24(5):1074-1081. PubMed ID: 29522202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis.
    Rao BB; Lashner B; Kowdley KV
    Inflamm Bowel Dis; 2018 Jan; 24(2):269-276. PubMed ID: 29361103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inflammatory bowel disease after liver transplantation for primary sclerosing cholangitis.
    Singh S; Loftus EV; Talwalkar JA
    Am J Gastroenterol; 2013 Sep; 108(9):1417-25. PubMed ID: 23896954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of colonic neoplasia after liver transplantation for primary sclerosing cholangitis.
    Hanouneh IA; Macaron C; Lopez R; Zein NN; Lashner BA
    Inflamm Bowel Dis; 2012 Feb; 18(2):269-74. PubMed ID: 21425212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis.
    Boonstra K; Weersma RK; van Erpecum KJ; Rauws EA; Spanier BW; Poen AC; van Nieuwkerk KM; Drenth JP; Witteman BJ; Tuynman HA; Naber AH; Kingma PJ; van Buuren HR; van Hoek B; Vleggaar FP; van Geloven N; Beuers U; Ponsioen CY;
    Hepatology; 2013 Dec; 58(6):2045-55. PubMed ID: 23775876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary sclerosing cholangitis as an independent risk factor for colorectal cancer in the context of inflammatory bowel disease: a review of the literature.
    Wang R; Leong RW
    World J Gastroenterol; 2014 Jul; 20(27):8783-9. PubMed ID: 25083052
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis Predicts Poorer Clinical Outcomes.
    Peverelle M; Paleri S; Hughes J; De Cruz P; Gow PJ
    Inflamm Bowel Dis; 2020 Nov; 26(12):1901-1908. PubMed ID: 31944235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asymptomatic De Novo Inflammatory Bowel Disease Late After Liver Transplantation for Primary Sclerosing Cholangitis: A Case Report.
    Åberg F; Abdulle A; Mäkelä A; Nissinen M
    Transplant Proc; 2015 Nov; 47(9):2775-7. PubMed ID: 26680092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Characteristics, Associated Malignancies and Management of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients: A Multicentre Retrospective Cohort Study.
    Guerra I; Bujanda L; Castro J; Merino O; Tosca J; Camps B; Gutiérrez A; Gordillo Ábalos J; de Castro L; Iborra M; Carbajo AY; Taxonera C; Rodríguez-Lago I; Mesonero F; de Francisco R; Gómez-Gómez GJ; Chaparro M; Tardillo CA; Rivero M; Algaba A; Martín Arranz E; Cañete F; Vicente R; Sicilia B; Antolín B; Prieto V; Márquez L; Benítez JM; Camo P; Piqueras M; Gargallo CJ; Hinojosa E; Huguet JM; Pérez Calle JL; Van Domselaar M; Rodriguez C; Calvet X; Muñoz-Villafranca C; García-Sepulcre MF; Munoz-Garrido P; Fernández-Clotet A; Gómez Irwin L; Hernández S; Guardiola J; Sempere L; González Muñoza C; Hernández V; Beltrán B; Barrio J; Alba C; Moraleja I; López-Sanromán A; Riestra S; Martínez Montiel P; Garre A; Arranz L; García MJ; Martín Arranz MD; Corsino P; Arias L; Fernández-Salazar L; Fernández-Pordomingo A; Andreu M; Iglesias E; Ber Y; Mena R; Arroyo Villarino MT; Mora M; Ruiz L; López-Serrano P; Blazquez I; Villoria A; Fernández M; Bermejo F; Banales JM; Domènech E; Gisbert JP;
    J Crohns Colitis; 2019 Dec; 13(12):1492-1500. PubMed ID: 31063540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Primary Sclerosing Cholangitis on Risks of Cancer and Death in People With Inflammatory Bowel Disease, Based on Sex, Race, and Age.
    Trivedi PJ; Crothers H; Mytton J; Bosch S; Iqbal T; Ferguson J; Hirschfield GM
    Gastroenterology; 2020 Sep; 159(3):915-928. PubMed ID: 32445859
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.
    de Vries AB; Janse M; Blokzijl H; Weersma RK
    World J Gastroenterol; 2015 Feb; 21(6):1956-71. PubMed ID: 25684965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical management of inflammatory bowel disease in the organ recipient.
    Indriolo A; Ravelli P
    World J Gastroenterol; 2014 Apr; 20(13):3525-33. PubMed ID: 24707135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease.
    Brackmann S; Andersen SN; Aamodt G; Langmark F; Clausen OP; Aadland E; Fausa O; Rydning A; Vatn MH
    Scand J Gastroenterol; 2009; 44(1):46-55. PubMed ID: 18609187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of anti-TNF therapy for inflammatory bowel disease in liver transplant recipients for primary sclerosing cholangitis: A nationwide case series.
    Altwegg R; Combes R; Laharie D; De Ledinghen V; Radenne S; Conti F; Chazouilleres O; Duvoux C; Dumortier J; Leroy V; Treton X; Durand F; Dharancy S; Nachury M; Goutorbe F; Lamblin G; Boivineau L; Peyrin-Biroulet L; Pageaux GP
    Dig Liver Dis; 2018 Jul; 50(7):668-674. PubMed ID: 29655972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary sclerosing cholangitis associated with inflammatory bowel disease: an update.
    Rossi RE; Conte D; Massironi S
    Eur J Gastroenterol Hepatol; 2016 Feb; 28(2):123-31. PubMed ID: 26636407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk Factors and Outcomes of De Novo Cancers (Excluding Nonmelanoma Skin Cancer) After Liver Transplantation for Primary Sclerosing Cholangitis.
    Mouchli MA; Singh S; Loftus EV; Boardman L; Talwalkar J; Rosen CB; Heimbach JK; Wiesner RH; Hasan B; Poterucha JJ; Kymberly WD
    Transplantation; 2017 Aug; 101(8):1859-1866. PubMed ID: 28272287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory bowel disease with primary sclerosing cholangitis: A Danish population-based cohort study 1977-2011.
    Sørensen JØ; Nielsen OH; Andersson M; Ainsworth MA; Ytting H; Bélard E; Jess T
    Liver Int; 2018 Mar; 38(3):532-541. PubMed ID: 28796371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Preexisting Inflammatory Bowel Disease on the Outcome of Liver Transplantation for Primary Sclerosing Cholangitis.
    Irlès-Depé M; Roullet S; Neau-Cransac M; Dumortier J; Dharancy S; Houssel-Debry P; Boillot O; Chiche L; Laurent C; Laharie D; De Lédinghen V
    Liver Transpl; 2020 Nov; 26(11):1477-1491. PubMed ID: 32603007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.